Dual antiplatelet therapy use by Canadian cardiac surgeons | Zendy

Bobby Yanagawa | Zendy; Marc Ruel | Zendy; Christopher Bonneau | Zendy; Myunghyun M. Lee | Zendy; Jennifer Chung | Zendy; Sadek Al Shouli | Zendy; Andrew Fagan | Zendy; Abdulwahab Al Khalifa | Zendy; Christopher W. White | Zendy; Michael H. Yamashita | Zendy; Maria E. Currie | Zendy; Hwee Teoh | Zendy; H.E. Mewhort | Zendy; Subodh Verma | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dual antiplatelet therapy use by Canadian cardiac surgeons

Author(s) -

Bobby Yanagawa,

Marc Ruel,

Christopher Bonneau,

Myunghyun M. Lee,

Jennifer Chung,

Sadek Al Shouli,

Andrew Fagan,

Abdulwahab Al Khalifa,

Christopher W. White,

Michael H. Yamashita,

Maria E. Currie,

Hwee Teoh,

H.E. Mewhort,

Subodh Verma

Publication year - 2015

Publication title -

journal of thoracic and cardiovascular surgery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.458

H-Index - 192

eISSN - 1085-8687

pISSN - 0022-5223

DOI - 10.1016/j.jtcvs.2015.08.066

Subject(s) - medicine , dual (grammatical number) , intensive care medicine , cardiology , literature , art

Dual antiplatelet therapy is the cornerstone treatment for patients with acute coronary syndrome. Recent Canadian Guidelines recommend the use of dual antiplatelet therapy for 1 year after coronary artery bypass grafting in patients with acute coronary syndrome, but considerable variability remains.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research